Lotronex was initially launched in 2000, but was subsequently removed from the market in light of serious side effects attributed to the drug. It was re-launched in 2002 with a new label. At the time, the ’770 patent was...more
Mylan filed a complaint on April 25, 2014, challenging a letter decision by the FDA, addressing the marketing exclusivity eligibility of celecoxib Abbreviated New Drug Application applicants. Mylan then filed a motion for...more
The Hatch-Waxman Litigation and Life Sciences practice groups at Robins, Kaplan, Miller & Ciresi L.L.P. are pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the...more
4/1/2014
/ Abbreviated New Drug Application (ANDA) ,
Burden of Proof ,
Claim Construction ,
Claim Preclusion ,
Eli Lilly ,
Federal Rule 12(b)(6) ,
Food and Drug Administration (FDA) ,
GlaxoSmithKline ,
Hatch-Waxman ,
Inter Partes Reexamination ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent-in-Suit ,
Patents ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prior Art ,
Settlement ,
Subject Matter Jurisdiction ,
Written Descriptions